7LRY

Structure of HIV-1 Reverse Transcriptase in complex with DNA, (-)FTC-TP, and CA(2+) ion

Summary for 7LRY

• Entry DOI: 10.2210/pdb7lry/pdb
• Descriptor: Reverse transcriptase p66, [[(2R,5S)-5-(4-azanyl-5-fluoranyl-2-oxidanylidene-pyrimidin-1-yl)-1,3-oxathiolan-2-yl]methoxy-oxidanyl-phosphoryl] phosphono hydrogen phosphate, Reverse transcriptase p51, ... (11 entities in total)
• Functional Keywords: human immunodeficiency virus 1, protein/dsdna, aptamer, dntp, transferase, transferase-dna complex, transferase/dna
• Biological source: Human immunodeficiency virus type 1 (HIV-1); More
• Total number of polymer chains: 6
• Total formula weight: 254833.14

Authors

Hoang, A.,Ruiz, F.X.,Arnold, E. (deposition date: 2021-02-17, release date: 2022-02-23, Last modification date: 2023-10-18)

Primary citation

Ruiz, F.X.,Hoang, A.,Dilmore, C.R.,DeStefano, J.J.,Arnold, E.
Structural basis of HIV inhibition by L-nucleosides: Opportunities for drug development and repurposing.
Drug Discov Today, 27:1832-1846, 2022

PubMed Abstract: Infection with HIV can cripple the immune system and lead to AIDS. Hepatitis B virus (HBV) is a hepadnavirus that causes human liver diseases. Both pathogens are major public health problems affecting millions of people worldwide. The polymerases from both viruses are the most common drug target for viral inhibition, sharing common architecture at their active sites. The L-nucleoside drugs emtricitabine and lamivudine are widely used HIV reverse transcriptase (RT) and HBV polymerase (Pol) inhibitors. Nevertheless, structural details of their binding to RT(Pol)/nucleic acid remained unknown until recently. Here, we discuss the implications of these structures, alongside related complexes with L-dNTPs, for the development of novel L-nucleos(t)ide drugs, and prospects for repurposing them.

PubMed: 35218925
DOI: 10.1016/j.drudis.2022.02.016

Experimental method

X-RAY DIFFRACTION (2.45 Å)